Skip to main content

Table 4 Signal detection for anticancer agent-associated lethal hypersensitivity reactions

From: Hypersensitivity reactions to anticancer agents: Data mining of the public version of the FDA adverse event reporting system, AERS

 

N

PRR (χ2)

ROR (95% two-sided CI)

IC (95% two-sided CI)

EBGM (95% one-sided CI)

paclitaxel

12

2.623 * (10.495)

2.631 * (1.492, 3.770)

1.165 * (0.363, 1.967)

1.992 (1.237)

docetaxel

17

4.224 * (38.715)

4.247 * (2.635, 5.858)

1.800 * (1.121, 2.478)

3.268 * (2.062)

doxorubicin

9

1.728 (2.086)

1.731 (0.900, 2.563)

0.614 (-0.305, 1.533)

1.401 (0.819)

5-fluorouracil

10

2.281 * (5.977)

2.286 * (1.228, 3.344)

0.964 * (0.089, 1.838)

1.735 (1.037)

cyclophosphamide

9

1.169 (0.083)

1.170 (0.608, 1.731)

0.127 (-0.792, 1.046)

1.047 (0.613)

  1. The total number of co-occurrences with lethal hypersensitivity reactions was 2,397.
  2. N: the number of co-occurrences of each anticancer agent out of 2,397 pairs, PRR: the proportional reporting ratio, ROR: the reporting odds ratio, IC: the information component, EBGM: the empirical Bayes geometric mean.
  3. *: signal detected, see “Methods” for the detection criteria.